Skip to main content

Table 2 Change in evaluated clinical outcome measures after treatment

From: Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA

 

All sample (N = 395)

Respondersa (N = 194)

No responders (N = 201)

P-value

Headache days/month

−11.3 ± 10.7

−15.3 ± 10.2

−7.4 ± 7.3

< 0.0001

Moderate-severe headache days/month

−7.3 ± 7.0

−8.5 ± 8.9

−3.6 ± 8.1

< 0.0001

≥50% headache days rate

51.4%

66.5%

36.8%

< 0.0001

≥50% moderate-severe headache days rate

54.2%

70.6%

38.3%

< 0.0001

Conversion to episodic migraine

52.9%

68.0%

38.3%

< 0.0001

≥50% pain intensity reduction

35.8%

50.0%

21.0%

< 0.0001

Acute treatment use (pills/month)

−24.9 ± 26.5

−34.2 ± 52.7

−14.1 ± 37.9

< 0.0001

≥50% acute treatment reduction (pills/month)

60.4%

69.6%

49.3%

< 0.0001

Conversion from medication overuse to non-medication overuse

37.5%

44.8%

30.3%

0.004

≥50% MIDAS score reduction rate

49.1%

NA

NA

NA

  1. aResponders were patients who presented a ≥ 50% improvement in MIDAS score after two cycles of OnabotulinumtoxinA. †P-values are assessed between responders and non-responders. Unpaired t-test were used for quantitative variables and Pearson’s Chi-squared test with Yate’s continuity correction for dichotomous variables